Veracyte, Inc. share price logo

Veracyte, Inc. Share Price

NASDAQ: VCYT

Mid Cap

$30.38

+0.36

(+1.22%)

as on

Veracyte, Inc. Stock Performance

as on March 31, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $29.88
    $30.71
    downward going graph

    1.65%

    Downside

    1.09%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $22.61
    $50.71
    downward going graph

    25.58%

    Downside

    66.92%

    Upside

    downward going graph

Veracyte, Inc. share price movements today

Previous Close
$30.01
Open
$30.06
Volume
1.2M
Day's Low - High
$29.88 - $30.71
52 Week Low - High
$22.61 - $50.71

Veracyte, Inc. Historical Returns

1 Month Return
-13.23 %
3 Month Return
-27.7 %
1 Year Return
+ 2.66 %
3 Year Return
+ 36.5 %
5 Year Return
-43.37 %

Veracyte, Inc. Stock Fundamentals & Key Indicators

Check Veracyte, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.4B

EPS (TTM)

1.648

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

7.12%

PE Ratio (TTM)

37.12

Industry PE ratio

7.887522123893805

PEG Ratio

0

EBITDA

84.4M

Revenue (TTM)

517.1M

Profit Margin

12.83%

Return On Equity TTM

5.34%

Veracyte, Inc. Stock Valuation

Track how Veracyte, Inc. P/E has moved over time to understand its valuation trends.

Veracyte, Inc. in the last 5 years

  • Overview

  • Trends

Lowest (-187.55x)

September 30, 2024

Industry (7.89x)

March 31, 2026

Today (37.12x)

March 31, 2026

Highest (63.11x)

December 31, 2024

LowHigh

Today’s Price to Earnings Ratio: 37.12x

Veracyte, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Veracyte, Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Veracyte, Inc. image
Veracyte, Inc.
BUY$2.4B-43.37%37.1212.83%
Idexx Laboratories, Inc. image
Idexx Laboratories, Inc.
BUY$44.6B13.85%42.7524.62%
Waters Corporation image
Waters Corporation
HOLD$28.8B3.24%26.8920.30%
Thermo Fisher Scientific, Inc. image
Thermo Fisher Scientific, Inc.
BUY$175.8B5.19%26.6715.05%
Agilent Technologies Inc. image
Agilent Technologies Inc.
BUY$31.7B-11.9%24.7318.26%
See all

Stock Returns calculator for Veracyte, Inc. Stock including INR - Dollar returns

The Veracyte, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Veracyte, Inc. investment value today

Current value as on today

₹1,13,543

Returns

₹13,543

(+13.54%)

Returns from Veracyte, Inc. Stock

₹2,462 (+2.46%)

Dollar Impact

₹11,081 (+11.08%)

Analyst Recommendation on Veracyte, Inc. Stock

Based on 15 analysts

BUY

73.33%

Buy

20.00%

Hold

6.67%

Sell

Based on 15 analysts, 73.33% of analysts recommend a 'BUY' rating for Veracyte, Inc.. Average target price of $47

Veracyte, Inc. Share Price Target

Get share price movements and forecasts by analysts on Veracyte, Inc..

What analysts predicted

35.36%UPSIDE

Target Price

$47

Current Price

$30.38

Analyzed by

15 Analysts

Target

$47.00

Veracyte, Inc. target price $47, a slight upside of 35.36% compared to current price of $30.38. According to 15 analysts rating.

Veracyte, Inc. Stock’s Investor Sentiment and Interest

Search interest for Veracyte, Inc. Stock has increased by 59% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:59% versus previous 30 day period

Veracyte, Inc. Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
90
98
96
114
115
118
114
130
131
140
Gross Profit
62
68
62
77
79
78
79
89
91
104
Operating Income
-31
-35
-4
4
12
4
2
-5
22
25
EBITDA
-22
-24
1
13
22
9
6
6
24
45
Interest Expense
0
0
-
0
0
-
-
-
-
-
Depreciation
7
6
5
5
5
6
5
5
5
5
Income Before Tax
-29
-30
-1
7
16
3
7
1
18
40
Income Tax Expense
0
-2
0
1
1
-1
0
2
0
0
Net Income
-29
-28
-1
5
15
5
7
0
19
41
Net Profit Margin
-32.87%
-28.81%
-1.92%
5.01%
13.08%
4.31%
6.16%
-0.75%
14.51%
29.26%

Veracyte, Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
65
71
92
120
117
219
296
361
445
517
Gross Profit
39
43
58
83
76
145
194
248
298
360
Operating Income
-28
-26
-22
-15
-35
-81
-41
-85
16
74
EBITDA
-25
-23
-17
-7
-26
-60
-6
-49
49
89
Interest Expense
2
4
1
0
0
0
0
0
0
0
Depreciation
-
3
3
4
7
19
25
27
23
21
Income Before Tax
-31
-31
-22
-12
-34
-81
-36
-76
25
68
Income Tax Expense
2
5
1
3
0
-6
0
-2
1
1
Net Income
-31
-31
-22
-12
-34
-75
-36
-74
24
66
Net Profit Margin
-48.18%
-43.09%
-25.00%
-10.47%
-29.71%
-34.42%
-12.33%
-20.61%
5.41%
12.83%

Veracyte, Inc. Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-28
-1
5
15
5
7
0
19
49
Operating Cash Flow
15
-8
29
29
24
5
33
44
52
Investing Cash Flow
-2
2
-2
-2
-54
-51
0
48
-5
Financing Cash Flow
0
0
0
10
-4
-6
0
2
0
Change in Cash
13
-7
26
38
-34
-52
33
96
47

Veracyte, Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-31
-22
-12
-34
-75
-36
-74
24
66
Operating Cash Flow
-23
-13
-3
-9
-31
7
44
75
136
Investing Cash Flow
-1
-1
-42
-3
-739
-29
15
-56
-9
Financing Cash Flow
0
59
127
203
596
3
2
4
-4
Change in Cash
-25
44
81
190
-176
-18
62
23
123

Global Institutional Holdings in Veracyte, Inc.

Funds
Holdings
State Street Corp
5.29%
Amova Asset Management Americas, Inc
1.58%
Artisan Partners Limited Partnership
7.88%
BAMCO Inc
1.11%
Geode Capital Management, LLC
2.38%
See all

Veracyte, Inc. News & Key Events

  • img

    Today's Timeline - 16 February

    Mon, 07:24 PM

    -

    Veracyte to report fourth-quarter 2025 results on Feb. 25, with strong earnings and revenue growth expectations.

    Tue, 06:37 AM

    -

    UBS reaffirms Buy rating on Veracyte, projecting 2026 revenue guidance of $570-$582 million, indicating significant upside potential.

Insights on Veracyte, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 4 quarters, 114.47M → 140.63M (in $), with an average increase of 6.5% per quarter

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, VCYT has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, -980.0K → 41.14M (in $), with an average increase of 79.3% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Idexx Laboratories, Inc. has given 32.9% return, outperforming this stock by 31.7%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, VCYT stock has moved down by -8.9%

About Veracyte, Inc.

veracyte is a pioneering genomic diagnostics company. our tests are dramatically improving clinical outcomes for patients by resolving inconclusive results from traditional diagnostic methods. we ask the right questions to resolve ambiguity and bring assurance to light, rendering tens of thousands of costly and unnecessary surgeries truly unnecessary. we are giving patients a clearer path forward. through scientific rigor we employ the best tools, best science and best minds to create tests that enable a more accurate diagnosis without the need for risky, costly and often unnecessary surgery. veracyte consistently brings to bear evidence that is unprecedented in genomic tests, thereby changing today's clinical practice standards. we are making a difference in the lives of physicians and patients. we are doing something real. .
OrganisationVeracyte, Inc.
Headquarters6000 Shoreline Court, South San Francisco, CA, United States, 94080
IndustryHealth Technology
CEOMr. Marc A. Stapley
E-voting on sharesClick here to vote

Key Management of Veracyte, Inc.

Name

Title

Dr. Keith Gligorich Ph.D.

Senior Vice President of Global Operations

Dr. Kevin Richard Haas Ph.D.

Chief Development and Technology Officer

Mr. Steven French

Senior VP & Chief Information Officer

Ms. Karen Possemato

Senior Vice President of Corporate Marketing, Communications & Commercial Operations

Ms. Corinne Danan

Senior Vice President

Ms. Annie McGuire

Executive VP, General Counsel & Chief People Officer

Dr. John Leite Ph.D.

Global Chief Commercial Officer

Mr. Jonathan Wygant

VP & Chief Accounting Officer

Mr. Marc A. Stapley

CEO & Director

Dr. Phillip G. Febbo M.D.

Chief Scientific & Medical Officer

FAQs

What is Veracyte, Inc. share price today?

Veracyte, Inc. share price today is $30.38 as on at the close of the market. Veracyte, Inc. share today touched a day high of $30.71 and a low of $29.88.

What is the 52 week high and 52 week low for Veracyte, Inc. share?

Veracyte, Inc. share touched a 52 week high of $50.71 on and a 52 week low of $22.61 on . Veracyte, Inc. stock price today i.e. is closed at $30.38,which is 40.09% down from its 52 week high and 34.37% up from its 52 week low.

What is Veracyte, Inc.'s market capitalisation today?

Veracyte, Inc. market capitalisation is $0.00T as on .

How to invest in Veracyte, Inc. Stock (VCYT) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Veracyte, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Veracyte, Inc. Shares that will get you 0.0494 shares as per Veracyte, Inc. share price of $30.38 per share as on March 31, 2026 at 1:29 am IST.

What is the minimum amount required to buy Veracyte, Inc. Stock (VCYT) from India?

Indian investors can start investing in Veracyte, Inc. (VCYT) shares with as little as ₹94.702 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹947.02 in Veracyte, Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Veracyte, Inc. share’s latest price of $30.38 as on March 31, 2026 at 1:29 am IST, you will get 0.3292 shares of Veracyte, Inc.. Learn more about fractional shares .

What are the returns that Veracyte, Inc. has given to Indian investors in the last 5 years?

Veracyte, Inc. stock has given -43.37% share price returns and 29.05% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?